MA33855B1 - Dérivés de benzamide substitués - Google Patents
Dérivés de benzamide substituésInfo
- Publication number
- MA33855B1 MA33855B1 MA35019A MA35019A MA33855B1 MA 33855 B1 MA33855 B1 MA 33855B1 MA 35019 A MA35019 A MA 35019A MA 35019 A MA35019 A MA 35019A MA 33855 B1 MA33855 B1 MA 33855B1
- Authority
- MA
- Morocco
- Prior art keywords
- lower alkyl
- disorders
- phenyl
- optionally substituted
- heterocycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
L'invention concerne des composés de formule i, dans laquelle r est l'hydrogène ou un alkyle inférieur ; r1 est -(ch2)n-(o)o-hétérocycloalkyle ou -c(o)-hétérocycloalkyle, le groupe hétérocycloalkyle étant éventuellement substitué par un alkyle inférieur, un hydroxy, un halogène ou par -(ch2)p-aryle ; n est 0, 1 ou 2 ; o est 0 ou 1 ; p est 0, 1 ou 2 ; r2 est cf3, cycloalkyle, éventuellement substitué par un alcoxy inférieur ou un halogène, ou est indan-2-yle, ou est hétérocycloalkyle, éventuellement substitué par hétéroaryle, ou est aryle ou hétéroaryle, les cycles aromatiques étant éventuellement substitués par un ou deux substituants, choisis parmi un alkyle inférieur, un halogène, un hétéroaryle, hydroxy, cf3, ocf3, och2cf3, och2-cycloalkyle, och2c(ch2oh)(ch2cl)(ch3), s-alkyle inférieur, alcoxy inférieur, ch2-alcoxy inférieur, alcynyle inférieur ou cyano, ou par -c(o)-phényle, -o-phényle, -o-ch2-phényle, phényle ou -ch2-phényle, et les cycles phényle pouvant éventuellement être substitués par un halogène, -c(o)-alkyle inférieur, -c(o)oh ou -c(o)o-alkyle inférieur, ou les cycles aromatiques étant éventuellement substitués par hétérocycloalkyle, och2-oxétan-3-yle ou o-tétrahydropyran-4-yle, éventuellement substitué par un alkyle inférieur ; x est une liaison, -nr'-, -ch2nh-, -chr''-, -(chr'')q-o-, -o-(chr'')q- ou -(ch2)2- ; y est une liaison ou -ch2-, r' l'hydrogène ou un alkyle inférieur, r'' est l'hydrogène, un alkyle inférieur, cf3, un alcoxy inférieur, q est 0, 1, 2 ou 3 ; ou un de leurs sels d'addition acide pharmaceutiquement appropriés. Il a maintenant été découvert que les composés de formule i ont une bonne affinité avec les récepteurs associés aux amines traces (taar), notamment taar1. Les composés peuvent être utilisés pour le traitement de la dépression, des troubles de l'anxiété, du trouble bipolaire, du trouble déficitaire de l'attention avec hyperactivité (tdah), des troubles associés au stress, des troubles psychotiques tels que la schizophrénie, des maladies neurologiques telles que la maladie de parkinson, des troubles neurodégénératifs tels que la maladie d'alzheimer, de l'épilepsie, de la migraine, de l'hypertension, de l'abus de substances et des troubles métaboliques tels que les troubles de l'alimentation, le diabète, les complications du diabète, l'obésité, la dyslipidémie, les troubles de la consommation et de l'assimilation d'énergie, les troubles et dysfonctionnements de l'homéostasie de la température corporelle, les troubles du sommeil et du rythme circadien, et les troubles cardiovasculaires
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09180504 | 2009-12-22 | ||
PCT/EP2010/070045 WO2011076678A1 (fr) | 2009-12-22 | 2010-12-17 | Dérivés de benzamide substitués |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33855B1 true MA33855B1 (fr) | 2012-12-03 |
Family
ID=43544985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35019A MA33855B1 (fr) | 2009-12-22 | 2012-06-29 | Dérivés de benzamide substitués |
Country Status (25)
Country | Link |
---|---|
US (4) | US9452980B2 (fr) |
EP (2) | EP2516392A1 (fr) |
JP (2) | JP6109575B2 (fr) |
KR (1) | KR101461296B1 (fr) |
CN (2) | CN105254623A (fr) |
AR (1) | AR079542A1 (fr) |
AU (1) | AU2010335277B2 (fr) |
BR (1) | BR112012015168B1 (fr) |
CA (1) | CA2780161C (fr) |
CL (1) | CL2012001673A1 (fr) |
CO (1) | CO6531470A2 (fr) |
CR (1) | CR20120275A (fr) |
EC (1) | ECSP12011999A (fr) |
IL (1) | IL219437A (fr) |
MA (1) | MA33855B1 (fr) |
MX (1) | MX2012007409A (fr) |
MY (1) | MY176030A (fr) |
NZ (1) | NZ599577A (fr) |
PE (1) | PE20121395A1 (fr) |
RU (1) | RU2595902C2 (fr) |
SG (1) | SG181874A1 (fr) |
TW (1) | TWI409261B (fr) |
UA (1) | UA113141C2 (fr) |
WO (1) | WO2011076678A1 (fr) |
ZA (1) | ZA201203137B (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
US9132136B2 (en) * | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
US9073911B2 (en) * | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
US9029370B2 (en) * | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
US9181230B2 (en) * | 2012-01-12 | 2015-11-10 | Hoffmann-La Roche Inc. | Morpholine compounds and uses thereof |
WO2014041007A1 (fr) * | 2012-09-14 | 2014-03-20 | F. Hoffmann-La Roche Ag | Dérivés de pyrazole-carboxamide en tant que modulateurs de taar pour utilisation dans le traitement de plusieurs troubles, tels que la dépression, le diabète et la maladie de parkinson |
KR101676208B1 (ko) * | 2012-09-17 | 2016-11-14 | 에프. 호프만-라 로슈 아게 | 트라이아졸 카복스아미드 유도체 |
CN108250128A (zh) * | 2012-09-27 | 2018-07-06 | 江苏先声药业有限公司 | 作为钾通道调节剂的化合物 |
BR112015009990A2 (pt) * | 2012-11-07 | 2017-07-11 | Hoffmann La Roche | derivados de pirazina |
US9045477B2 (en) * | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
CN103242191B (zh) * | 2013-05-06 | 2015-05-20 | 暨南大学 | 一种防治老年痴呆症的化合物及其制备方法和用途 |
WO2015165085A1 (fr) * | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Dérivés de morpholine-pyridine |
JP6275870B2 (ja) * | 2014-05-28 | 2018-02-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Taar1モジュレーターとしての5−オキサ−2−アザビシクロ[2.2.2]オクタン−4−イル及び5−オキサ−2−アザビシクロ[2.2.1]ヘプタン−4−イル誘導体 |
WO2016015333A1 (fr) * | 2014-08-01 | 2016-02-04 | F.Hoffmann-La Roche Ag | Dérivés de 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl |
CN104292143A (zh) * | 2014-08-17 | 2015-01-21 | 湖南华腾制药有限公司 | 一种2-(4-溴苄基)吡咯烷的制备方法 |
CN104478798B (zh) * | 2014-12-18 | 2017-01-18 | 武汉华纳联合药业有限公司 | N‑氨基烷基磺酰基‑3‑吡啶甲酰胺衍生物及其在制备治疗心脑血管病药物中的应用 |
MY195528A (en) * | 2016-03-17 | 2023-01-30 | Hoffmann La Roche | 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar |
EP3463359A4 (fr) * | 2016-06-02 | 2020-08-26 | Purdue Pharma LP | Agonistes du récepteur 1 associé à une amine à l'état de trace et agonistes partiels pour le traitement de la douleur |
CN106432057A (zh) * | 2016-09-17 | 2017-02-22 | 青岛云天生物技术有限公司 | 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法 |
AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
US20230416199A1 (en) * | 2020-10-23 | 2023-12-28 | Icahn School Of Medicine At Mount Sinai | Inhibitors of amino acid transport |
CN114478360B (zh) * | 2022-02-10 | 2023-08-15 | 江苏海洋大学 | 一种苯甲酰胺类衍生物及其制备方法和应用 |
WO2023235844A2 (fr) * | 2022-06-03 | 2023-12-07 | Axsome Therapeutics | Composés de carbamoyl phénylalaninol utiles en tant qu'agonistes de taar1 |
Family Cites Families (164)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US609558A (en) * | 1898-08-23 | Lantern | ||
US440195A (en) * | 1890-11-11 | Press for bundle-wrapping | ||
US2731471A (en) | 1956-01-17 | Nxg hi | ||
US661266A (en) * | 1899-11-27 | 1900-11-06 | Francis T Roots | Triple sign. |
US2161938A (en) | 1934-07-31 | 1939-06-13 | Soc Of Chemical Ind | Imidazolines |
US2457047A (en) | 1946-02-13 | 1948-12-21 | Monsanto Chemicals | 2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same |
DE842065C (de) | 1950-07-30 | 1952-06-23 | Bayer Ag | Verfahren zur Herstellung stickstoffhaltiger heterocyclischer Verbindungen |
US2778836A (en) | 1954-04-02 | 1957-01-22 | Union Chimique Belge Sa | Substituted 2-methyl-delta2 imidazolines |
US2744909A (en) | 1955-06-27 | 1956-05-08 | Bristol Lab Inc | 2-(ortho-phenylbenzyl) imidazoline and acid addition salts |
US2744910A (en) | 1955-06-27 | 1956-05-08 | Bristol Lab Inc | 2-(ortho-benzylbenzyl)-imidazoline and acid addition salts |
US2919274A (en) | 1957-09-17 | 1959-12-29 | Sahyun Melville | Amidines |
GB877306A (en) | 1958-04-21 | 1961-09-13 | Pfizer & Co C | Halogenated derivatives of tetrahydro-1-naphthyl cyclic amidines |
DE1083803B (de) | 1958-05-30 | 1960-06-23 | Bayer Ag | Verfahren zur Herstellung von Derivaten der Anthranil-N-carbonsaeure |
DE1121054B (de) | 1960-11-23 | 1962-01-04 | Merck Ag E | Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen |
US3190802A (en) | 1961-10-09 | 1965-06-22 | Boehringer Sohn Ingelheim | Shaving composition and method of using same |
DE1150180B (de) | 1962-04-12 | 1963-06-12 | Merck Ag E | Mittel zur Vorbehandlung der Haut fuer die Rasur |
FR1355049A (fr) | 1962-04-12 | 1964-03-13 | Merck Ag E | Agent pour le traitement préalable de la peau en vue du rasage |
US3459763A (en) | 1966-01-25 | 1969-08-05 | Geigy Chem Corp | Certain amino imidazole derivatives |
ES323985A1 (es) | 1966-02-26 | 1966-12-16 | Blade Pique Juan | Procedimiento para la obtenciën de derivados del imidazol |
GB1180794A (en) * | 1966-08-05 | 1970-02-11 | Boehringer Sohn Ingelheim | Novel Arylhydrazino-Imidazolines and Preparation Thereof |
US3377247A (en) | 1967-04-28 | 1968-04-09 | Dow Chemical Co | Antidepressant method |
US3586695A (en) | 1968-01-26 | 1971-06-22 | Dow Chemical Co | Substituted imidazolinyl indoles |
US3577415A (en) * | 1968-12-23 | 1971-05-04 | Robins Co Inc A H | 1-substituted-3-substituted phenoxypyrrolidines |
US3577428A (en) | 1969-04-14 | 1971-05-04 | Colgate Palmolive Co | 2-amino-4-aryloxyalkyl-4-alkyl-2-oxazolines |
BE754820R (fr) | 1969-08-13 | 1971-02-15 | Schering Ag | Nouveaux derives de pyrimidine, leurs procedes de preparation et leurs |
US3818094A (en) | 1969-08-28 | 1974-06-18 | Boehringer Sohn Ingelheim | Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2) |
US3622579A (en) | 1969-08-28 | 1971-11-23 | Boehringer Sohn Ingelheim | Derivatives of 2-anilino-1,3-diazacyclopentene-(2) |
US3660423A (en) | 1970-02-13 | 1972-05-02 | Dow Chemical Co | 2-(substituted benzyl)methyl-2-imidazolines |
GB1333471A (en) | 1971-01-27 | 1973-10-10 | Labaz | Imidazoline derivatives and process for preparing the same |
DE2123246C2 (de) | 1971-05-11 | 1982-11-25 | Basf Ag, 6700 Ludwigshafen | 6-[p-(β-Phenyläthylaminoacetylamino)-phenyl]-4,5-dihydropyridazon-(3) |
DE2253555A1 (de) | 1972-11-02 | 1974-05-09 | Hoechst Ag | Oxazolo-pyrimidine und verfahren zu ihrer herstellung |
US3981814A (en) * | 1973-09-18 | 1976-09-21 | Givaudan Corporation | Bacteriostatic substituted benzanilide compositions and methods for their use |
CH609558A5 (en) | 1973-09-18 | 1979-03-15 | Givaudan & Cie Sa | Antibacterial composition |
US4125620A (en) | 1974-10-01 | 1978-11-14 | Boehringer Ingelheim Gmbh | 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof |
DE2446758C3 (de) | 1974-10-01 | 1979-01-04 | C.H. Boehringer Sohn, 6507 Ingelheim | 2-(2-Fluor-6-trifluormethylphenylimino)-imidazolidin, dessen Säureadditionssalze, Verfahren zur Herstellung dieser Verbindungen und deren Verwendung bei der Bekämpfung der Hypertonie |
US3992403A (en) | 1975-05-30 | 1976-11-16 | Schering Corporation | 2-Imidazolines and their use as hypoglycemic agents |
GB1538097A (en) | 1976-01-26 | 1979-01-10 | Lafon Labor | Substituted phenyl-amidines |
US4323570A (en) | 1978-11-15 | 1982-04-06 | Beiersdorf Aktiengesellschaft | Substituted aminopyrimidines |
DE2849537C2 (de) | 1978-11-15 | 1983-03-17 | Beiersdorf Ag, 2000 Hamburg | Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
AU518569B2 (en) | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
US4311840A (en) | 1980-11-13 | 1982-01-19 | E. R. Squibb & Sons, Inc. | 2,3,6,7-Tetrahydro-2-thioxo-4H-oxazolo[3,2-a]-1,3,5 triazin-4-ones |
US4735959A (en) | 1981-01-10 | 1988-04-05 | Dr. Karl Thomae Gmbh | Carboxylic acid amides and pharmaceutical compositions containing them |
DE3133887A1 (de) | 1981-08-27 | 1983-03-10 | Bayer Ag, 5090 Leverkusen | 2-arylhydrazino-2-imidazoline, deren acylderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von endo- und ektoparasiten |
ES518818A0 (es) | 1982-01-27 | 1984-06-16 | Pfizer | Un procedimiento para la preparacion de una composicion ectoparasiticida, especialmente acaricida, o antihelmintica. |
DE3302021A1 (de) | 1983-01-22 | 1984-07-26 | Basf Ag, 6700 Ludwigshafen | 6-aryl-4,5-dihydro-3(2h)-pyridazinone, ihre herstellung und verwendung |
US4540705A (en) | 1983-03-14 | 1985-09-10 | Sterling Drug Inc. | Antidepressant imidazolines and related compounds |
DE3583900D1 (de) | 1984-06-06 | 1991-10-02 | Abbott Lab | Adrenergische verbindungen. |
DK302185A (da) | 1984-07-05 | 1986-01-06 | Rolland Sa A | 2-amino-oxazoliner samt fremgangsmaade til deres fremstilling |
JPS61233678A (ja) | 1985-04-09 | 1986-10-17 | Maruko Seiyaku Kk | ベンジルピペラジン誘導体 |
US4665095A (en) | 1985-12-11 | 1987-05-12 | Abbott Laboratories | Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion |
GB2215206B (en) | 1988-02-29 | 1991-07-03 | Farmos Oy | 4-substituted imidazole derivatives useful in perioperative care |
DE3830054A1 (de) * | 1988-09-03 | 1990-03-15 | Boehringer Mannheim Gmbh | Phenylamide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
FR2645860B1 (fr) | 1989-04-14 | 1991-07-26 | Sarget Lab | Nouvelles aryloxymethyl-5 amino-2 oxazolines, syntheses et applications therapeutiques |
FI894911A0 (fi) | 1989-10-17 | 1989-10-17 | Farmos Oy | En terapeutiskt vaerdefull foerening. |
EP0440195B1 (fr) | 1990-01-31 | 1997-07-30 | Fuji Photo Film Co., Ltd. | Produit photographique couleur à l'halogénure d'argent |
EP0805677B1 (fr) | 1993-10-13 | 2005-06-15 | H. Joseph Horacek | Preparation de clonidine a liberation prolongee |
EP0661266A1 (fr) | 1993-12-27 | 1995-07-05 | Toa Eiyo Ltd. | Composés cycliques aminés substitués comme 5HT2 antagonistes |
GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
DE19514579A1 (de) | 1995-04-20 | 1996-10-24 | Boehringer Ingelheim Kg | Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz |
US5610174A (en) | 1995-06-02 | 1997-03-11 | Synaptic Pharmaceutical Corporation | Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence |
ES2157366T3 (es) * | 1995-06-09 | 2001-08-16 | Hoffmann La Roche | Derivados de pirimidindiona, pirimidintriona, triacindiona como antagonistas de receptores alfa-1-adrenergicos. |
GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
CN1155574C (zh) * | 1996-08-15 | 2004-06-30 | 先灵公司 | 醚毒蕈碱性拮抗剂 |
US5969137A (en) | 1996-09-19 | 1999-10-19 | Virginia Commonwealth University | Benzylamidine derivatives with serotonin receptor binding activity |
GB9625145D0 (en) | 1996-12-03 | 1997-01-22 | Smithkline Beecham Plc | Novel compounds |
IL123232A0 (en) | 1997-02-11 | 1999-11-30 | Lilly Co Eli | Medicament for inhibiting glucose metabolism deterioration |
US5866579A (en) | 1997-04-11 | 1999-02-02 | Synaptic Pharmaceutical Corporation | Imidazole and imidazoline derivatives and uses thereof |
AR016817A1 (es) | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
US6184242B1 (en) | 1997-09-04 | 2001-02-06 | Syntex Usa (Llc) | 2-(substituted-phenyl)amino-imidazoline derivatives |
NZ331480A (en) * | 1997-09-04 | 2000-02-28 | F | 2-(Arylphenyl)amino-imidazoline derivatives and pharmaceutical compositions |
JP4783502B2 (ja) | 1997-12-04 | 2011-09-28 | アラーガン、インコーポレイテッド | α2Bまたは2B/2Cアドレナリン受容体において作動剤様活性を示す置換イミダゾール誘導体 |
US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
ATE239013T1 (de) | 1997-12-19 | 2003-05-15 | Lilly Co Eli | Hypoglykamische imidazoline derivate |
AU3534699A (en) | 1998-04-23 | 1999-11-08 | Takeda Chemical Industries Ltd. | Naphthalene derivatives, their production and use |
DE19826517B4 (de) | 1998-06-15 | 2006-03-23 | Baxter Healthcare S.A. | Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette |
ES2150378B1 (es) | 1998-08-07 | 2001-07-01 | Esteve Labor Dr | Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p. |
CA2246027A1 (fr) | 1998-08-27 | 2000-02-27 | Virginia Commonwealth University | Derives de benzylamidine avec activite de fixation provenant des recepteurs de la serotonine |
WO2000026191A1 (fr) * | 1998-11-04 | 2000-05-11 | Meiji Seika Kaisha, Ltd. | Derives de picolinamide et pesticides contenant ces derives comme ingredient actif |
DE69926806D1 (de) | 1998-12-18 | 2005-09-22 | Bristol Myers Squibb Pharma Co | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren |
US6777428B1 (en) * | 1999-02-10 | 2004-08-17 | Eli Lilly And Company | 5-HT1f agonist |
NZ513726A (en) * | 1999-03-17 | 2001-09-28 | Astrazeneca Ab | Amide derivatives |
US6291476B1 (en) * | 1999-05-12 | 2001-09-18 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
US6355660B1 (en) * | 1999-07-20 | 2002-03-12 | Dow Agrosciences Llc | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation |
PE20010781A1 (es) | 1999-10-22 | 2001-08-08 | Takeda Chemical Industries Ltd | Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion |
JP2001151742A (ja) | 1999-11-26 | 2001-06-05 | Mitsui Chemicals Inc | アニリド誘導体及びそれを含有する抗不整脈剤 |
FR2802533B1 (fr) * | 1999-12-17 | 2002-02-15 | Sanofi Synthelabo | Phenoxypropanolamines, leur preparation et leur application en therapeutique |
JP2001302643A (ja) | 2000-04-21 | 2001-10-31 | Suntory Ltd | 環状アミジン化合物 |
JO2654B1 (en) * | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
AU2001292617A1 (en) | 2000-09-12 | 2002-03-26 | Oregon Health And Science University | Mammalian receptor genes and uses |
CA2427900A1 (fr) | 2000-11-14 | 2002-05-23 | F. Hoffmann-La Roche Ag | Derives de 2-phenylaminoimidazoline phenyle cetone substitues utilises comme antagonistes de la prostaglandine i2 |
WO2002053544A1 (fr) | 2000-12-29 | 2002-07-11 | Darwin Discovery Ltd. | Utilisations pharmaceutiques et synthese de nicotinanilide-n-oxydes |
JP2004532187A (ja) | 2001-01-25 | 2004-10-21 | ギルフォード ファーマシュウティカルズ インコーポレイテッド | 三置換カルボサイクリックサイクロフィリン結合化合物とその用途 |
US7429593B2 (en) * | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
IL147921A0 (en) | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
EP1505068A4 (fr) * | 2002-04-23 | 2008-03-19 | Shionogi & Co | DERIVE DE PYRAZOLO(1,5-a)PYRIMIDINE ET INHIBITEUR DE LA NAD(P)H OXYDASE CONTENANT LEDIT DERIVE |
TW200306783A (en) | 2002-04-29 | 2003-12-01 | Fmc Corp | Pesticidal heterocycles |
AU2003243318A1 (en) | 2002-05-29 | 2003-12-19 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
UA77536C2 (en) * | 2002-07-03 | 2006-12-15 | Lundbeck & Co As H | Secondary aminoaniline piperidines as mch1 antagonists and their use |
KR100492252B1 (ko) | 2002-08-09 | 2005-05-30 | 한국화학연구원 | 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법 |
DE10250743A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
WO2004054977A1 (fr) * | 2002-12-13 | 2004-07-01 | Cytopia Pty Ltd | Inhibiteurs de kinase a base de nicotinamide |
CA2510471A1 (fr) * | 2002-12-19 | 2004-07-08 | Neurogen Corporation | Analogues d'arylamide d'acide biphenyl-4-carboxylique substitues |
EP1590333A4 (fr) * | 2003-01-23 | 2008-04-30 | Crystalgenomics Inc | Inhibiteur de glycogene synthase kinase 3beta, composition et procede de preparation associe |
US6933311B2 (en) | 2003-02-11 | 2005-08-23 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
DE10306250A1 (de) * | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP2415760A3 (fr) | 2003-02-20 | 2012-02-22 | Encysive Pharmaceuticals, Inc. | Antagonistes du CCR-9 |
BRPI0409211A (pt) * | 2003-04-18 | 2006-03-28 | Lilly Co Eli | composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto |
WO2005014554A1 (fr) | 2003-08-08 | 2005-02-17 | Astex Therapeutics Limited | Composes 1h-indazole-3-carboxamide utilises comme modulateurs de la mapkap kinase |
GB2406856B (en) | 2003-10-07 | 2005-10-19 | Renovis Inc | Amide compounds as ion channel ligands and uses thereof |
JP4667384B2 (ja) * | 2003-10-07 | 2011-04-13 | レノビス, インコーポレイテッド | イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法 |
ES2297502T3 (es) | 2003-10-23 | 2008-05-01 | F. Hoffmann-La Roche Ag | Derivados de triaza-espiropiperidinas para uso como inhibidores de glyt-1 en el tratamiento de trastornos neurologicos y neuropsiquiatricos. |
EP1712242B1 (fr) | 2003-12-26 | 2018-05-30 | Masatoshi Hagiwara | Methode destinee a reguler la phosphorylation de la proteine sr, et agents antiviraux comprenant le regulateur de l'activite de la proteine sr comme principe actif |
US8404747B2 (en) | 2004-03-05 | 2013-03-26 | The General Hospital Corporation | Compositions and methods for modulating interaction between polypeptides |
PL1761520T3 (pl) | 2004-06-23 | 2008-12-31 | Lilly Co Eli | Inhibitory kinazy |
TW200606137A (en) | 2004-07-02 | 2006-02-16 | Sankyo Co | Urea derivatives |
US20080261952A1 (en) | 2004-08-16 | 2008-10-23 | Jason Bloxham | Aryl Urea Derivatives for Treating Obesity |
DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
SI1805164T1 (sl) * | 2004-09-29 | 2011-05-31 | Mitsubishi Tanabe Pharma Corp | 6-(piridinil)-4-pirimidonski derivati kot inhibitorji tau protein kinaze 1 |
JPWO2006051851A1 (ja) | 2004-11-10 | 2008-05-29 | わかもと製薬株式会社 | 2,3,4,5−テトラヒドロ−1h−1,5−ベンゾジアゼピン誘導体、及び、医薬組成物 |
US20060111392A1 (en) * | 2004-11-23 | 2006-05-25 | Wood Michael R | Substituted biaryl-carboxylate derivatives |
JPWO2006070878A1 (ja) | 2004-12-28 | 2008-06-12 | アステラス製薬株式会社 | カルボン酸誘導体またはその塩 |
GB0611907D0 (en) * | 2006-06-15 | 2006-07-26 | Glaxo Group Ltd | Compounds |
EP1845975A1 (fr) | 2005-01-21 | 2007-10-24 | Astex Therapeutics Limited | Combinaisons d'inhibiteurs de pyrazole kinase et d'autres agents antitumoraux |
JP2008534685A (ja) | 2005-04-05 | 2008-08-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 炎症性疾患の治療に有用な置換ベンジルイミダゾール |
JP2008540441A (ja) | 2005-05-03 | 2008-11-20 | バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト | 殺虫性の置換されたアミノアルキル複素環式及びヘテロアリール誘導体 |
EP1900087A2 (fr) | 2005-07-06 | 2008-03-19 | Cambridge Semiconductor Limited | Systemes de commande pour alimentation en mode commute |
JP2007051121A (ja) | 2005-07-22 | 2007-03-01 | Taiho Yakuhin Kogyo Kk | プロスタグランジンd合成酵素を阻害するピリミジン化合物 |
WO2007017728A2 (fr) | 2005-08-05 | 2007-02-15 | Orchid Research Laboratories Limited | Nouveaux composes heterocycliques |
JP2009506047A (ja) | 2005-08-25 | 2009-02-12 | シェーリング コーポレイション | 機能的に選択的なα2Cアドレナリン受容体アゴニストとしてのイミダゾール誘導体 |
KR20080050490A (ko) | 2005-09-16 | 2008-06-05 | 애로우 쎄라퓨틱스 리미티드 | 바이페닐 유도체, 및 c형 간염 치료에 있어서의 그의 용도 |
AP2008004459A0 (en) | 2005-10-06 | 2008-06-30 | Univ Massachusetts | Composition and sythesis of new reagents for inhibition of HIV replication |
US20070197529A1 (en) | 2005-12-01 | 2007-08-23 | Viviana Braude | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard |
JP2007191471A (ja) | 2005-12-21 | 2007-08-02 | Sankyo Co Ltd | ウレア誘導体を含有する医薬 |
US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
AU2007209380B2 (en) | 2006-01-27 | 2011-12-08 | F. Hoffmann-La Roche Ag | Use of 4-imidazole derivatives for CNS disorders |
JP5182088B2 (ja) | 2006-04-19 | 2013-04-10 | アステラス製薬株式会社 | アゾールカルボキサミド誘導体 |
TW200808705A (en) * | 2006-06-15 | 2008-02-16 | Sanofi Aventis | Aryl- and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics |
JP5028484B2 (ja) | 2006-06-28 | 2012-09-19 | グラクソ グループ リミテッド | Gpr38受容体媒介疾患の治療に有用なピペラジニル誘導体 |
CN101528710B (zh) | 2006-10-19 | 2012-11-07 | 弗·哈夫曼-拉罗切有限公司 | 氨基甲基-4-咪唑类 |
CA2668210C (fr) | 2006-10-31 | 2013-03-12 | Schering Corporation | Derives d'anilinopiperazine et leurs methodes d'utilisation |
JP2010509236A (ja) | 2006-11-03 | 2010-03-25 | アレテ セラピューティクス, インコーポレイテッド | 慢性関節リウマチの処置のための可溶性エポキシドヒドロラーゼ阻害剤 |
WO2008078762A1 (fr) * | 2006-12-26 | 2008-07-03 | Santen Pharmaceutical Co., Ltd. | Nouveau derive n-(2-aminophenyl)benzamide presentant une structure d'uree |
US7470684B2 (en) * | 2007-01-03 | 2008-12-30 | Hoffmann-La Roche Inc. | Spiropiperidine derivatives as NK3 antagonists |
UA98951C2 (ru) | 2007-02-02 | 2012-07-10 | Ф. Хоффманн-Ля Рош Аг | 2-аминооксазолины и лекарственное средство, которое их содержит |
KR101222412B1 (ko) | 2007-02-15 | 2013-01-15 | 에프. 호프만-라 로슈 아게 | Taar1 리간드로서의 2-아미노옥사졸린 |
WO2008141976A1 (fr) | 2007-05-22 | 2008-11-27 | Via Pharmaceuticals, Inc. | Inhibiteurs de diacylglycérol acyltransférase |
US8058299B2 (en) * | 2007-05-22 | 2011-11-15 | Via Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
US8367686B2 (en) | 2007-06-07 | 2013-02-05 | Intra-Cellular Therapies, Inc. | Heterocycle compounds and uses thereof |
JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
AR066911A1 (es) | 2007-06-08 | 2009-09-23 | Janssen Pharmaceutica Nv | Derivados de piperidina / piperazina |
JP2010535172A (ja) * | 2007-08-02 | 2010-11-18 | エフ.ホフマン−ラ ロシュ アーゲー | Cns障害の処置のためのベンズアミド誘導体の使用 |
JP5341084B2 (ja) | 2007-08-03 | 2013-11-13 | エフ.ホフマン−ラ ロシュ アーゲー | Taar1リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体 |
US8093428B2 (en) | 2007-10-26 | 2012-01-10 | Janssen Pharmaceutica N.V. | Synthesis of quaternary salt compounds |
CN101434570B (zh) | 2007-11-16 | 2011-02-02 | 上海医药工业研究院 | 吡咯烷衍生物及其制备方法和应用 |
AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
BRPI0916363A2 (pt) | 2008-07-24 | 2018-05-29 | Hoffmann La Roche | derivados de 4,5-di-hidro-oxazol-2-ila |
WO2010020556A1 (fr) * | 2008-08-22 | 2010-02-25 | Evotec Neurosciences Gmbh | Nouveaux antagonistes du récepteur de la bradykinine b1 |
JP5605844B2 (ja) | 2008-10-17 | 2014-10-15 | 塩野義製薬株式会社 | 血管内皮リパーゼ阻害活性を有する酢酸アミド誘導体 |
ES2432070T3 (es) | 2009-02-24 | 2013-11-29 | Respiratorius Ab | Diazaheteroarilos broncodilatadores novedosos |
CA2793276A1 (fr) | 2009-03-27 | 2010-09-30 | Zacharon Pharmaceuticals, Inc. | Modulateurs de la biosynthese des gangliosides |
JP5381257B2 (ja) | 2009-04-09 | 2014-01-08 | ユニマテック株式会社 | 含フッ素ボロン酸エステル化合物の製造方法 |
WO2010118347A2 (fr) | 2009-04-10 | 2010-10-14 | Zacharon Pharmaceuticals, Inc. | Modulateurs de la biosynthèse de o-glycanes |
JP5542214B2 (ja) * | 2009-10-27 | 2014-07-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr1受容体アンタゴニストとしての複素環化合物 |
US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
-
2010
- 2010-12-16 US US12/969,613 patent/US9452980B2/en active Active
- 2010-12-17 SG SG2012046249A patent/SG181874A1/en unknown
- 2010-12-17 BR BR112012015168-1A patent/BR112012015168B1/pt active IP Right Grant
- 2010-12-17 NZ NZ599577A patent/NZ599577A/en unknown
- 2010-12-17 MY MYPI2012002780A patent/MY176030A/en unknown
- 2010-12-17 MX MX2012007409A patent/MX2012007409A/es unknown
- 2010-12-17 CA CA2780161A patent/CA2780161C/fr active Active
- 2010-12-17 AU AU2010335277A patent/AU2010335277B2/en active Active
- 2010-12-17 JP JP2012545252A patent/JP6109575B2/ja active Active
- 2010-12-17 CN CN201510671612.8A patent/CN105254623A/zh active Pending
- 2010-12-17 WO PCT/EP2010/070045 patent/WO2011076678A1/fr active Application Filing
- 2010-12-17 RU RU2012129737/04A patent/RU2595902C2/ru active
- 2010-12-17 KR KR1020127018988A patent/KR101461296B1/ko active IP Right Grant
- 2010-12-17 EP EP10793256A patent/EP2516392A1/fr not_active Withdrawn
- 2010-12-17 PE PE2012000869A patent/PE20121395A1/es not_active Application Discontinuation
- 2010-12-17 CN CN2010800592019A patent/CN102686563A/zh active Pending
- 2010-12-17 UA UAA201208947A patent/UA113141C2/uk unknown
- 2010-12-17 EP EP17151744.4A patent/EP3187490B1/fr active Active
- 2010-12-20 AR ARP100104762A patent/AR079542A1/es active IP Right Grant
- 2010-12-20 TW TW099144833A patent/TWI409261B/zh active
-
2012
- 2012-04-24 CO CO12067324A patent/CO6531470A2/es active IP Right Grant
- 2012-04-25 IL IL219437A patent/IL219437A/en active IP Right Grant
- 2012-04-30 ZA ZA2012/03137A patent/ZA201203137B/en unknown
- 2012-05-23 CR CR20120275A patent/CR20120275A/es unknown
- 2012-06-20 CL CL2012001673A patent/CL2012001673A1/es unknown
- 2012-06-22 EC ECSP12011999 patent/ECSP12011999A/es unknown
- 2012-06-29 MA MA35019A patent/MA33855B1/fr unknown
-
2015
- 2015-11-06 JP JP2015218849A patent/JP6567393B2/ja active Active
-
2016
- 2016-05-18 US US15/157,734 patent/US10501411B2/en active Active
-
2019
- 2019-10-15 US US16/653,210 patent/US20200048194A1/en not_active Abandoned
-
2020
- 2020-11-12 US US17/096,438 patent/US11697636B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33855B1 (fr) | Dérivés de benzamide substitués | |
MA35192B1 (fr) | Derives de pyrazole | |
MA32486B1 (fr) | Derives de 4,5- dihydrooxazol-2-yle | |
MA31165B1 (fr) | Nouvelles 2-aminooxazolines servant de ligands du taar1 pour des troubles du snc | |
CN104136413B (zh) | 用于预防或治疗癫痫症的苯基氨基甲酸酯化合物 | |
CN101096348A (zh) | 新萘化合物、其制备方法及其药物组合物 | |
ECSP12012098A (es) | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos | |
MA42442B1 (fr) | Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate | |
JP7279758B2 (ja) | テトラヒドロナフタレン誘導体 | |
MA35062B1 (fr) | Dérivés d'amines hétérocycliques | |
MA35194B1 (fr) | Derives de benzamide substitues | |
MA38012B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5 | |
MA35133B1 (fr) | Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5 | |
NO20091936L (no) | 4-imidazoliner som TAAR ligander | |
MX2009005920A (es) | Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina. | |
RU2006105779A (ru) | Индол-5-ильные сульфонамидные производные, их получение и их применение в качестве модуляторов 5-нт-6 | |
MA37944A1 (fr) | Dérivés de pyrazole-carboxamide en tant que modulateurs de taar pour utilisation dans le traitement de plusieurs troubles, tels que la dépression, le diabète et la maladie de parkinson | |
KR20050075281A (ko) | 씨엔에스 질병의 치료를 위한 도파민-디3 리간드로서헤테로아렌 카복스아미드의 용도 | |
EP0447292A1 (fr) | Dérivés de 4-(aminométhyl)pipéridine, leur préparation et leur application en thérapeutique | |
EP2516383A1 (fr) | Nouveaux dérivés d'aminotétraline | |
HRP940960A2 (en) | N-substituted azabicycloheptane derivatives, the preparation and use thereof | |
MX2009004617A (es) | 2-imidazoles sustituidos como moduladores de los receptores asociados con trazas de amina. | |
EP3204374A1 (fr) | Dérivés d'isoindoline | |
WO2007090720A3 (fr) | Utilisation de 2-imidazoles pour le traitement de troubles du système nerveux central | |
BG62349B2 (bg) | N-заместени производни на 3-азабицикло/3.2.0/хептан като невролептици |